Next generation biopharmaceuticals

Press & News

2019-03-28

[read more]

About Affibody

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that target psoriasis and rare Immunoglobulin G (IgG)-mediated autoimmune diseases. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

In addition, to its portfolio of innovative drug projects the company offers the half-life extension technology, Albumod™, for outlicensing.

Affibody AB is a holding of Patricia Industries.

”Our mission is to improve the lives of patients with serious diseases by being a research-driven company with a long term commitment to development of proteinbased drugs”

Affibodys latest Press releases

2019-03-28

Interview with Affibody’s CEO (in Swedish)

[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report Q1 (May 17, 2019)